| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | -0.052 | 0.2 |
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | -0.052 | 0.2 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | CCT036477 | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.073 | 0.2 |
| mRNA | RITA | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | BIX-01294 | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | -0.038 | 0.2 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |